Cryoport (CYRX) Scheduled to Post Quarterly Earnings on Tuesday

Cryoport (NASDAQ:CYRX - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Cryoport has set its FY 2024 guidance at EPS.Persons interested in listening to the company's earnings conference call can do so using this link.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.19). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The firm had revenue of $57.26 million during the quarter, compared to analysts' expectations of $58.27 million. On average, analysts expect Cryoport to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cryoport Stock Up 3.8 %

Shares of CYRX stock traded up $0.62 during trading hours on Wednesday, reaching $16.81. The company had a trading volume of 475,876 shares, compared to its average volume of 441,239. The company has a debt-to-equity ratio of 0.82, a quick ratio of 11.16 and a current ratio of 11.73. Cryoport has a twelve month low of $9.00 and a twelve month high of $24.17. The company has a market capitalization of $826.38 million, a P/E ratio of -7.64 and a beta of 1.60. The stock's fifty day simple moving average is $16.90 and its 200 day simple moving average is $15.06.

Analysts Set New Price Targets

CYRX has been the subject of a number of recent research reports. Jefferies Financial Group initiated coverage on Cryoport in a research note on Thursday, April 4th. They issued a "buy" rating and a $21.00 target price for the company. Needham & Company LLC lowered their price objective on Cryoport from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. UBS Group raised their price objective on Cryoport from $14.50 to $17.00 and gave the company a "neutral" rating in a research note on Friday, March 15th. Finally, Stephens restated an "equal weight" rating and set a $17.00 price objective on shares of Cryoport in a research note on Wednesday, March 13th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $18.63.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 2,631 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the transaction, the chief executive officer now owns 692,182 shares of the company's stock, valued at approximately $12,140,872.28. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Ramkumar Mandalam sold 3,217 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total value of $47,225.56. Following the sale, the director now owns 43,187 shares of the company's stock, valued at approximately $633,985.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jerrell Shelton sold 2,631 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the sale, the chief executive officer now directly owns 692,182 shares in the company, valued at approximately $12,140,872.28. The disclosure for this sale can be found here. Insiders have sold a total of 73,940 shares of company stock valued at $1,147,538 in the last quarter. Insiders own 10.10% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.